Screener
Monte Rosa Therapeutics, Inc. GLUE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands) | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net (loss) income | $(87,900) | $34,590 |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 11,919 | 10,192 |
| Depreciation | 3,943 | 4,173 |
| Net accretion of discounts/premiums on marketable securities | (1,960) | (1,766) |
| Gain on disposal of property and equipment | — | (59) |
| Changes in operating assets and liabilities |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s stock-based comp?
- Monte Rosa Therapeutics, Inc. (GLUE) reported stock-based comp of $5.97M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s stock-based comp increased by 22.0% year-over-year, from $4.89M to $5.97M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s stock-based comp has grown at a 38.0% compound annual growth rate (CAGR), from $5.2M to $18.87M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Monte Rosa Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude